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Bell’s palsy:
new evidence provides a definitive drug therapy strategy
Bell’s palsy is acute, idiopathic, unilateral
paralysis of the facial nerve1 and most GPs
will see a new case about once every
5 years. Although most patients recover
well, up to 30% have a poor outcome, with
persistent facial weakness, psychological
difficulties, and facial pain. The rapid, often
painful onset of facial weakness is
distressing for patients, leading them to
present urgently to their GP. Primary care
management has included various options,
such as prednisolone and/or antiviral
drugs, or neither, but evidence for these or
other strategies has been weak or absent.
This persisting uncertainty about ideal
management can be disconcerting for GPs
and their patients.
In 2001, the American Academy of
Neurology published guidelines on the
management of Bell’s palsy, concluding
that, while the benefit of steroids and/or
aciclovir had not been established, the
available evidence indicated that steroids
were ‘probably effective’, and that aciclovir
combined with prednisolone was ‘possibly
effective’.1 Subsequently, two articles
published in the British Medical Journal
triggered controversy when they
recommended the early use of steroids
and aciclovir,2,3 although no further reliable
data had been published since the
American guideline. After decades of little
persuasive evidence, four randomised
controlled trials, involving over 1800
patients, have recently been published,
and their results allow much more robust
conclusions regarding drug treatment of
Bell’s palsy.4–7
Steroids definitely improve outcome,
based on the results of two large primary
care based trials which addressed this
question. The Scottish Bell’s palsy trial4
included 551 patients recruited from
primary care, and showed that 83% of
patients treated with prednisolone within
72 hours of onset (50 mg/day for 10 days)
had recovered compared to 63.6% who
received placebo at 3 months (number
needed to treat [NNT] = 6) and this result
remained significant at 9 months (NNT = 8).
The recent Swedish trial5 involving 839
patients confirmed this, with 72% of the
steroid group (10 days of prednisolone
starting at 60 mg/day for 5 days, then
reduced by 10 mg/day, started within
72 hours of onset) who achieved full
recovery at 12 months versus 57% in the
control group.
Antiviral drugs do not improve outcome.
The Scottish trial used aciclovir
2000 mg/day for 10 days, and led to no
improvement in recovery either in addition
to, or instead of, prednisolone. Two
Japanese hospital based trials6,7 compared
prednisolone alone (starting dose
60 mg/day) with prednisolone plus
valaciclovir (a pro-drug of aciclovir). One
study (150 patients recruited) reported a
negative result (valaciclovir offered no
advantage over prednisolone alone).6 The
second study (296 recruited) reported a
positive outcome,7 but this result was
compromised by a number of serious
methodological flaws, including an
inadequate randomisation procedure,
single blind design, and a 25% drop out
rate (not included in the analyses).8
Following the publication of these three
trials in 2007,4,6,7 some commentators still
recommended the use valaciclovir for
those with severe facial weakness,9,10
despite the evidence of lack of
effectiveness. Most recently, the Swedish
study5 has hopefully put the matter beyond
doubt, with no evidence that valaciclovir
was effective in the management of Bell’s
palsy.11
Yet some may still be tempted to
recommend antiviral treatment. Their
rationale is driven by the suspicion that
many cases may be due to reactivation of
herpes simplex virus (HSV), although this
aetiological hypothesis has never been
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proven. It is also suggested that varicella
zoster reactivation leading to facial palsy
without rash (zoster sine herpete) may
account for a proportion of Bell’s palsy.
Serological studies were carried out in the
two Japanese studies and revealed
evidence of varicella zoster reactivation in
23/296 (8%)7 and 28/150 (19%).6 The latter
study also measured HSV serology which
indicated reactivation in 29/150 (19%).6
Antiviral enthusiasts suggest that
because the dose of aciclovir used in the
Scottish trial4 was insufficient to treat
varicella zoster and because patients were
not tested serologically, unwitting inclusion
of varicella zoster patients may have
biased the study, producing an erroneous
negative result. However, this argument is
insufficient to explain the lack of effect
seen in the Swedish study,5 as the dose of
valaciclovir (3000 mg/day for 7 days) was
sufficient to treat varicella zoster as well as
HSV (serology was not performed). The
concern regarding varicella zoster
reactivation has led to the suggestion that
viral serology should be obtained at the
outset of management, and the selection
of treatment be guided by the results. We
do not regard this as being feasible, at
least within UK primary care, nor is it
evidence based.
In summary, we may now draw some
robust, evidence-based conclusions
regarding treatment of patients with Bell’s
palsy (see Box 1). Although the outcome
for most patients with Bell’s palsy without
treatment is good, steroids within 72 hours
of onset significantly improve the
proportion of those recovering fully,4,5 and
should be offered to all appropriate
patients. Prednisolone 50 mg/day for
10 days is effective,4 and perhaps more
straightforward for patients and
prescribers than 60 mg for 5 days, then
reducing by 10 mg/day over the next
5 days;5 neither regime led to unacceptable
adverse effects. There is no evidence to
recommend the use of steroids beyond the
72-hour time window at present. Antiviral
drugs should not be used routinely on the
basis of current evidence, and the failure of
their effectiveness must lead us to
question the notion that Bell’s palsy is due
to viral reactivation in most cases. Finally,
we should remember that no matter how
seductive an aetiological theory might
appear, firm evidence of successful
treatment is required before accepting it
and recommending widespread use of
drug therapy. The results of these recent
trials allow GPs to approach the
management of this distressing condition
with confidence.
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• All patients presenting with Bell’s palsy
within 72 hours of onset should be
considered for treatment with a short
course of steroids.
• Antiviral therapy does not improve
outcome beyond steroids alone.
Box 1. Key evidence-based
messages.
